What are the cardiovascular benefits of Eli Lilly's Foundayo?

Foundayo reduced the risk of major cardiovascular events by 16% and the risk of death from any cause by 57% in adults with type 2 diabetes and obesity.

How does Foundayo compare to insulin glargine for diabetes and obesity?

Foundayo showed a lower risk of cardiovascular events and death, along with greater reductions in blood sugar and weight, compared to insulin glargine, which caused weight gain.

When will Eli Lilly seek US approval for Foundayo for type 2 diabetes?

Eli Lilly intends to submit an application for U.S. approval of Foundayo for type 2 diabetes by the end of the second quarter.

Home / Health / Lilly's New Obesity Pill Slashes Heart Risks

Lilly's New Obesity Pill Slashes Heart Risks

16 Apr

•

Summary

New obesity pill Foundayo reduced cardiovascular events by 16%.
Patients on Foundayo saw a 57% lower risk of death from any cause.
Foundayo led to greater weight and blood sugar reductions.

Lilly's New Obesity Pill Slashes Heart Risks

Eli Lilly announced encouraging results from a late-stage trial for its new obesity pill, Foundayo, on April 16, 2026. The study found that Foundayo significantly reduced the risk of major cardiovascular events in adults with type 2 diabetes and obesity.

Participants taking Foundayo experienced a 16% lower risk of heart attack, stroke, or cardiovascular death. Furthermore, the drug demonstrated a 57% reduction in the risk of death from any cause when compared to insulin glargine. The trial also revealed that patients on Foundayo achieved greater reductions in blood sugar and weight, while those on insulin glargine gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of the second quarter, utilizing the Commissioner's National Priority Review Voucher.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.